ReviewMolecular therapy : the journal of the American Society of Gene Therapy2009
Targeting cancer-initiating cells with oncolytic viruses.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 79 citations in OpenAlex.
- The pivotal role of autophagy in the pathogenesis and therapy of medulloblastoma.Future oncology (London, England) · 2024Review
- The role of oncolytic virotherapy and viral oncogenes in the cancer stem cells: a review of virus in cancer stem cells.Cancer cell international · 2023Review
- Article
- Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses.International journal of molecular sciences · 2022Review
- Progress of oncolytic virotherapy for neuroblastoma.Frontiers in pediatrics · 2022Review
- Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia.Signal transduction and targeted therapy · 2020Article
- Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma.Theranostics · 2019Article
- GOLPH2-regulated oncolytic adenovirus, GD55, exerts strong killing effect on human prostate cancer stem-like cells in vitro and in vivo.Acta pharmacologica Sinica · 2018Article
- 11R-P53 and GM-CSF Expressing Oncolytic Adenovirus Target Cancer Stem Cells with Enhanced Synergistic Activity.Journal of Cancer · 2017Article
- VSV based virotherapy in ovarian cancer: the past, the present and …future?Journal of Cancer · 2017Review
- Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.Oncotarget · 2016Article
- Oncolytic viruses against cancer stem cells: A promising approach for gastrointestinal cancer.World journal of gastroenterology · 2016Review
- Oncolytic virotherapy for urological cancers.Nature reviews. Urology · 2016Review
- GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells.Oncotarget · 2016Article
- Oncolytic herpes simplex virus kills stem-like tumor-initiating colon cancer cells.Molecular therapy oncolytics · 2016Article
- Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.Oncoimmunology · 2015Article
- Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.Journal of cellular and molecular medicine · 2015Article
- Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy.American journal of cancer research · 2015Article
- GFP stable transfection facilitated the characterization of lung cancer stem cells.Molecular biotechnology · 2014Article
- Cytotoxic effect of a combination of bluetongue virus and radiation on prostate cancer.Experimental and therapeutic medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Recent studies in a variety of leukemias and solid tumors indicate that there is significant heterogeneity with respect to tumor-forming ability within a given population of tumor cells, suggesting that only a subpopulation of cells is responsible for tumorigenesis. These cells have been commonly referred to as cancer stem cells (CSCs) or cancer-initiating cells (CICs). CICs have been shown to be relatively resistant to conventional anticancer therapies and are thus thought to be responsible for disease relapse. As such, they represent a potentially critical therapeutic target. Oncolytic viruses are in clinical trials for cancer and kill cells through mechanisms different from conventional therapeutics. Because these viruses are not susceptible to the same pathways of drug or radiation resistance, it is important to learn whether CICs are susceptible to oncolytic virus infection. Here we review the available data regarding the ability of several different oncolytic virus types to target CICs for destruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.